Tina Norton
Psychiatric/Mental Health · Hutchinson, KSNPI 1831435726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,635 and has fallen 60.2% since, to $651 in 2025.
Across 170 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$626
- AbbVie$588
- Vanda Pharmaceuticals Inc.$449
- Johnson & Johnson$381
- Alkermes, Inc.$371
- Teva Pharmaceuticals USA, Inc.$361
- plus $992 from 12 others
What the payments were for
- Food & beverage$3,767100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $626 |
| AbbVie | 39 | $588 |
| Vanda Pharmaceuticals Inc. | 13 | $449 |
| Johnson & Johnson | 19 | $381 |
| Alkermes, Inc. | 17 | $371 |
| Teva Pharmaceuticals USA, Inc. | 16 | $361 |
| Otsuka America Pharmaceutical, Inc. | 11 | $214 |
| Neurocrine Biosciences, Inc. | 8 | $170 |
| Supernus Pharmaceuticals, Inc. | 6 | $165 |
| Axsome Therapeutics, Inc. | 5 | $145 |
| Lundbeck LLC | 8 | $141 |
| Indivior Inc. | 3 | $45 |
| Biogen | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Cook Medical LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Corium, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,767 in reported general payments places this provider in the 85th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 75 | $109,237 |
| IngrezzaValbenazine Tosylate | 11 | $93,735 |
| AustedoDeutetrabenazine | 11 | $79,598 |
| RexultiBrexpiprazole | 49 | $67,907 |
| CaplytaLumateperone Tosylate | 29 | $51,626 |
| Invega SustennaPaliperidone Palmitate | 17 | $47,698 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $27,560 |
| Aripiprazole OdtAripiprazole | 23 | $20,434 |
| Aripiprazole | 189 | $12,457 |
| Paliperidone ErPaliperidone | 54 | $9,690 |
| QelbreeViloxazine Hcl | 16 | $9,540 |
| Asenapine Maleate | 30 | $8,313 |
| Olanzapine | 178 | $6,014 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $4,715 |
| TrintellixVortioxetine Hydrobromide | 11 | $4,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $588 | $109,23775 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $170 | $93,73511 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $361 | $79,59811 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $214 | $67,90749 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $626 | $51,62629 claims |
| Johnson & JohnsonInvega Sustenna | $381 | $47,69817 claims |
| Alkermes, Inc.Lybalvi | $371 | $27,56018 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $165 | $9,54016 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14 | $4,56611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Hutchinson
- Belinda BagbyHutchinson$39K
- Marie Maugans ColemanHutchinson$8K
- Susan RuleHutchinson$6K
- Eric ThomasonPittsburg$333K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
- Theresa MuellerOverland Park$14K
- Shiney ZchariaOlathe$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.